Rheum to Breathe Banner
Dr. John Cush Tweet
@RheumNow
Where are we now—and where are we going in ILD treatment? 📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE) Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush Tweet
@RheumNow
QD Clinic: Rapidly progressive RA ILD - or not? Dr. Richard Conway, a rheumatologist in Dublin, Ireland, discusses whether this case shows rapidly progressing RA-ILD, or not, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/YC8XFiqZmd
Dr. John Cush Tweet
@RheumNow
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/sSzMvDUMf5
Dr. John Cush Tweet
@RheumNow
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/WFwavo32rB
Dr. John Cush Tweet
@RheumNow
EULAR & European Respiratory Society have published clinical practice guidelines for ILD assoc w/ connective tissue diseases (SSc, RA, SjD, IIM, SLE, MCTD). 2 publications included Dz specific ILD management algorithms; use of Hi Res CT over Lung Bx; ILD risk factors
Dr. John Cush Tweet
@RheumNow
Connective tissue disease associated with interstitial lung disease (CTD-ILD) market is estimated to be $5.9 Billion USD in 2024 and is projected to grow to 9.3 billion, driven by increase in autoimmune Dz, adoption of biologics, ongoing clinical anti-fibrotic trials https://t.co/UqshQgNOau
Article

Rheumatoid Arthritis ILD Complications

Scott Matson, MD

I'm a pulmonologist at the University of Kansas in Kansas City, and I'm excited to talk about one of my favorite topics: treatment complications in rheumatoid arthritis- associated interstitial lung disease or RA-ILD. One of the reasons I think this is a pressing and important topic is what we'

Dr. John Cush Tweet
@RheumNow
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/Q8mMxtBgZZ

Therapeutic Updates

ILD Treatment and Guidelines

Hinze title card
Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.
Read Post

Campaign Videos

Podcasts

  • ILD Diagnosis, Screening and Monitoring
  • QD clinics on ILD - lessons from the Clinic #4
  • Rheum + Pulm Collaborations in ILD
×